Mineralys Therapeutics, Inc. MLYS Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Deferred Tax Assets, Operating Loss Carryforwards, State and Local at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local?
- Mineralys Therapeutics, Inc. (MLYS) reported deferred tax assets, operating loss carryforwards, state and local of $59.5M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards, state and local has grown at a 123.9% compound annual growth rate (CAGR), from $5.3M to $59.5M.